SSO can modulate different molecular targets involved in the pathogenesis of Alzheimer’s disease through alterations in nuclear factor kappa B/p38 mitogen-activated protein kinase/brain-derived neurotrophic factor/peroxisome proliferator-activated receptor gamma (NF-κB/p38MAPK/BDNF/PPAR-γ) and this can be attributed to the synergistic effect of their active components (60) (Figure 6). The gene discussed is BDNF; the disease is early-onset autosomal dominant Alzheimer disease.